TAVR Platform Drives Sales Growth
TAVR net sales increased 11.3% in Q2, driven by higher sales of the Edwards SAPIEN 3 Ultra RESILIA valve across the U.S., Europe, and Japan; foreign currency tailwinds added $8.4 million.
Edwards Lifesciences Corp is expected to release its Q3 2026 10-Q filing on October 28, 2026, after market close. Last quarter: Edwards Lifesciences delivered strong revenue growth in Q2 FY2026 driven by TAVR and TMTT, but net income fell 27.4% due to a $188.2 million tax valuation allowance.
EPS Estimate
$0.76
Revenue Estimate
$1.73B
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the EW page.
Drawn from management commentary in the Q2 2026 10-Q:
TAVR net sales increased 11.3% in Q2, driven by higher sales of the Edwards SAPIEN 3 Ultra RESILIA valve across the U.S., Europe, and Japan; foreign currency tailwinds added $8.4 million.
TMTT net sales surged 47.7% to $198.6 million, propelled by the PASCAL repair system, EVOQUE tricuspid replacement, and SAPIEN M3 mitral valve; the company received CE Mark for SAPIEN M3 RESILIA and FDA approval for TRIFORMIS RESILIA.
The effective tax rate jumped to 53.6% from 16.1% last year, mainly due to a $188.2 million non-cash valuation allowance against California R&D tax credits following budget legislation that permanently limited their utilization; the company also faces ongoing IRS transfer-pricing disputes that could materially impact future periods.
Revenue
$1.74B
+13.63% YoY
EPS (Diluted)
$0.42
-25.00% YoY
Gross Margin
77.5%
-0.1 pts YoY
Operating Income
$513.2M
+24.81% YoY
Add EW to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.